0001193125-23-281574.txt : 20231121 0001193125-23-281574.hdr.sgml : 20231121 20231121171154 ACCESSION NUMBER: 0001193125-23-281574 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231121 ITEM INFORMATION: Other Events FILED AS OF DATE: 20231121 DATE AS OF CHANGE: 20231121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 231429110 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 8-K 1 d586090d8k.htm 8-K 8-K
ACADIA PHARMACEUTICALS INC false 0001070494 0001070494 2023-11-21 2023-11-21

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 21, 2023

 

 

Acadia Pharmaceuticals Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   000-50768   06-1376651

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

12830 El Camino Real, Suite 400

San Diego, California

   92130
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 558-2871

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   ACAD   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01

Other Events.

On November 21, 2023, Acadia Pharmaceuticals Inc. (the “Company”) announced that Doug Williamson, M.D., Executive Vice President, Head of Research and Development, will be leaving the Company to pursue other opportunities. Dr. Williamson joined Acadia in January 2023 and will continue in his role during a transitional period. The Company has initiated a search for his replacement.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “will,” “continue” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this Current Report. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this Current Report include, but are not limited to, statements regarding Dr. Williamson’s anticipated departure from the Company, his continuing to serve in his current role during a transitional period and the Company’s search for a replacement EVP of Research and Development. Many factors may cause differences between current expectations and actual results, including the potential for Dr. Williamson to continue serving at the Company. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this Current Report are discussed in the Company’s filings with the Securities and Exchange Commission, including the sections titled “Risk Factors” contained therein. Except as required by law, the Company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Acadia Pharmaceuticals Inc.
Dated: November 21, 2023     By:  

/s/ Austin D. Kim

      Austin D. Kim
      Executive Vice President, General Counsel & Secretary
 EX-101.SCH 2 acad-20231121.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 acad-20231121_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 acad-20231121_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 21, 2023
Cover [Abstract]  
Entity Registrant Name ACADIA PHARMACEUTICALS INC
Amendment Flag false
Entity Central Index Key 0001070494
Document Type 8-K
Document Period End Date Nov. 21, 2023
Entity Incorporation State Country Code DE
Entity File Number 000-50768
Entity Tax Identification Number 06-1376651
Entity Address, Address Line One 12830 El Camino Real
Entity Address, Address Line Two Suite 400
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code (858)
Local Phone Number 558-2871
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol ACAD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 d586090d8k_htm.xml IDEA: XBRL DOCUMENT 0001070494 2023-11-21 2023-11-21 ACADIA PHARMACEUTICALS INC false 0001070494 8-K 2023-11-21 DE 000-50768 06-1376651 12830 El Camino Real Suite 400 San Diego CA 92130 (858) 558-2871 false false false false Common Stock, par value $0.0001 per share ACAD NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports acad-20231121.xsd acad-20231121_lab.xml acad-20231121_pre.xml d586090d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d586090d8k.htm": { "nsprefix": "acad", "nsuri": "http://www.acadia-pharm.com/20231121", "dts": { "schema": { "local": [ "acad-20231121.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "acad-20231121_lab.xml" ] }, "presentationLink": { "local": [ "acad-20231121_pre.xml" ] }, "inline": { "local": [ "d586090d8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-11-21_to_2023-11-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d586090d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-11-21_to_2023-11-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d586090d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.acadia-pharm.com//20231121/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001193125-23-281574-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-281574-xbrl.zip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end